资讯
Superluminal Medicines Raises $60M Series B to Advance Obesity Drug
📋总体概括
Superluminal Medicines, a Boston biotechnology company applying AI and machine learning to drug discovery, announced on September 3, 2026 the closing of an oversubscribed $60 million Series B financin
⚡关键信息
- ▸Superluminal Medicines, a Boston biotechnology company apply
📰 相关资讯（与本文相关的其他资讯）
本文由本站自动聚合，以下为原始来源：前往 unite.ai 阅读全文 →